Latest Dana-Farber Cancer Institute Stories
Although doctors have long known that people with Down syndrome have a heightened risk of developing acute lymphoblastic leukemia (ALL) during childhood, they haven't been able to explain why.
New therapies are needed to prevent and treat respiratory syncytial virus (RSV) – a potentially lethal respiratory infection that can severely affect infants, young children and the elderly.
Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer.
Comprehensive BMT(TM) will deliver an unmatched hematopoietic stem cell transplant (HSCT) data management solution for improved research and reporting SALT LAKE CITY, March 26, 2014 /PRNewswire/
The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults.
Dana-Farber Cancer Institute scientists have developed a mathematical model to predict how a patient's tumor is likely to behave and which of several possible treatments is most likely to be effective.
In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment.
Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors.
Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range.
- totally perplexed and mixed up.